The clinical progress of mRNA vaccines and immunotherapies

AJ Barbier, AY Jiang, P Zhang, R Wooster… - Nature …, 2022 - nature.com
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

[HTML][HTML] mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

L Schoenmaker, D Witzigmann, JA Kulkarni… - International journal of …, 2021 - Elsevier
A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they
have to be stored at (ultra) low temperatures. Understanding the root cause of the instability …

Lipids and lipid derivatives for RNA delivery

Y Zhang, C Sun, C Wang, KE Jankovic… - Chemical reviews, 2021 - ACS Publications
RNA-based therapeutics have shown great promise in treating a broad spectrum of
diseases through various mechanisms including knockdown of pathological genes …

[HTML][HTML] mRNA vaccines for COVID-19: what, why and how

JW Park, PNP Lagniton, Y Liu… - International journal of …, 2021 - ncbi.nlm.nih.gov
Abstract The Coronavirus disease-19 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), has impacted human lives in the most …

Challenges of storage and stability of mRNA-based COVID-19 vaccines

MN Uddin, MA Roni - Vaccines, 2021 - mdpi.com
In December 2019, a new and highly pathogenic coronavirus emerged—coronavirus
disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome …

Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects

E Kon, N Ad-El, I Hazan-Halevy… - Nature reviews clinical …, 2023 - nature.com
Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an
ongoing research area that started before these versatile nanoparticles were successfully …

Principles for designing an optimal mRNA lipid nanoparticle vaccine

E Kon, U Elia, D Peer - Current opinion in biotechnology, 2022 - Elsevier
mRNA Lipid nanoparticles (LNPs) have recently been propelled onto the center stage of
therapeutic platforms due to the success of the SARS-CoV-2 mRNA LNP vaccines (mRNA …

A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines

A Vander Straeten, M Sarmadi, JL Daristotle… - Nature …, 2024 - nature.com
Decentralized manufacture of thermostable mRNA vaccines in a microneedle patch (MNP)
format could enhance vaccine access in low-resource communities by eliminating the need …

Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine

H Muramatsu, K Lam, C Bajusz, D Laczkó, K Karikó… - Molecular Therapy, 2022 - cell.com
Lipid nanoparticle (LNP)-formulated nucleoside-modified mRNA vaccines have proven to be
very successful in the fight against the coronavirus disease 2019 (COVID-19) pandemic …

[HTML][HTML] The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case

EO Blenke, E Örnskov, C Schöneich, GA Nilsson… - Journal of …, 2023 - Elsevier
The remarkable impact of mRNA vaccines on mitigating disease and improving public
health has been amply demonstrated during the COVID-19 pandemic. Many new mRNA …